These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 7541527)

  • 21. Analytical evaluation of the new Prostatus PSA Free/Total assay for prostate-specific antigen as part of a screening study for prostate cancer.
    Blijenberg BG; Bangma CH; Kranse R; Eman I; Schröder FH
    Eur J Clin Chem Clin Biochem; 1997 Feb; 35(2):111-4. PubMed ID: 9056753
    [TBL] [Abstract][Full Text] [Related]  

  • 22. New developments in the standardization of total prostate-specific antigen.
    Blijenberg BG; Storm BN; Van Zelst BD; Kruger AE; Schröder FH
    Clin Biochem; 1999 Nov; 32(8):627-34. PubMed ID: 10638945
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Determination of the "reflex range" and appropriate cutpoints for percent free prostate-specific antigen in 413 men referred for prostatic evaluation using the AxSYM system.
    Vashi AR; Wojno KJ; Henricks W; England BA; Vessella RL; Lange PH; Wright GL; Schellhammer PF; Weigand RA; Olson RM; Dowell BL; Borden KK; Oesterling JE
    Urology; 1997 Jan; 49(1):19-27. PubMed ID: 9000179
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Repeat ultrasound guided prostate needle biopsy: use of free-to-total prostate specific antigen ratio in predicting prostatic carcinoma.
    Letran JL; Blase AB; Loberiza FR; Meyer GE; Ransom SD; Brawer MK
    J Urol; 1998 Aug; 160(2):426-9. PubMed ID: 9679891
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Variability of repeated serum prostate-specific antigen (PSA) measurements within less than 90 days in a well-defined patient population.
    Roehrborn CG; Pickens GJ; Carmody T
    Urology; 1996 Jan; 47(1):59-66. PubMed ID: 8560664
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Impact of free prostate-specific antigen on discordant measurement results of assays for total prostate-specific antigen.
    Semjonow A; Oberpenning F; Brandt B; Zechel C; Brandau W; Hertle L
    Urology; 1996 Dec; 48(6A Suppl):10-5. PubMed ID: 8973694
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial.
    Catalona WJ; Partin AW; Slawin KM; Brawer MK; Flanigan RC; Patel A; Richie JP; deKernion JB; Walsh PC; Scardino PT; Lange PH; Subong EN; Parson RE; Gasior GH; Loveland KG; Southwick PC
    JAMA; 1998 May; 279(19):1542-7. PubMed ID: 9605898
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Complexed prostate-specific antigen for early detection of prostate cancer in men with serum prostate-specific antigen levels of 2 to 4 nanograms per milliliter.
    Horninger W; Cheli CD; Babaian RJ; Fritsche HA; Lepor H; Taneja SS; Childs S; Stamey TA; Sokoll LJ; Chan DW; Brawer MK; Partin AW; Bartsch G
    Urology; 2002 Oct; 60(4 Suppl 1):31-5. PubMed ID: 12384160
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparative analysis of complexed prostate specific antigen, free prostate specific antigen and their ratio in detecting prostate cancer.
    Okihara K; Cheli CD; Partin AW; Fritche HA; Chan DW; Sokoll LJ; Brawer MK; Schwartz MK; Vessella RL; Loughlin KR; Johnston DA; Babaian RJ
    J Urol; 2002 May; 167(5):2017-23; discussion 2023-4. PubMed ID: 11956430
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Experience with an assay for prostate-specific antigen and transrectal ultrasonography in the diagnosis of prostate cancer.
    Heman-Ackah CA; Festenstein JB; Hibbert P; Harvey DJ; Bunce CJ; Gelister JS
    Br J Urol; 1997 Mar; 79(3):439-44. PubMed ID: 9117228
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Utilization of polyclonal serum prostate specific antigen levels in screening for prostate cancer: a comparison with corresponding monoclonal values.
    Terris MK; Stamey TA
    Br J Urol; 1994 Jan; 73(1):61-4. PubMed ID: 7507783
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Possibility of improving the acceptance rateof early detection testing for prostate cancerwith a one-step test for prostate-specific antigen in whole blood.
    Berg W; Linder C; Eschholz G; Link S; Schubert J
    Urol Int; 1999; 63(2):102-6. PubMed ID: 10592497
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Determination of prostate-specific antigen in serum by immunoradiometric assay.
    Lindstedt G; Jacobsson A; Lundberg PA; Hedelin H; Pettersson S; Unsgaard B
    Clin Chem; 1990 Jan; 36(1):53-8. PubMed ID: 1688745
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Physiological variation of serum prostate specific antigen in the 4.0 to 10.0 ng./ml. range in male volunteers.
    Prestigiacomo AF; Stamey TA
    J Urol; 1996 Jun; 155(6):1977-80. PubMed ID: 8618301
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Diagnostic value of percent free prostate-specific antigen: retrospective analysis of a population-based screening study with emphasis on men with PSA levels less than 3.0 ng/mL.
    Törnblom M; Norming U; Adolfsson J; Becker C; Abrahamsson PA; Lilja H; Gustafsson O
    Urology; 1999 May; 53(5):945-50. PubMed ID: 10223488
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evaluation of proprostate specific antigen for early detection of prostate cancer in men with a total prostate specific antigen range of 4.0 to 10.0 ng/ml.
    Khan MA; Partin AW; Rittenhouse HG; Mikolajczyk SD; Sokoll LJ; Chan DW; Veltri RW
    J Urol; 2003 Sep; 170(3):723-6. PubMed ID: 12913682
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The enhanced detection of persistent disease after prostatectomy with a new prostate specific antigen immunoassay.
    Takayama TK; Vessella RL; Brawer MK; Noteboom J; Lange PH
    J Urol; 1993 Aug; 150(2 Pt 1):374-8. PubMed ID: 7686983
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The percentage of free prostatic-specific antigen is also useful in men with normal digital rectal examination and serum prostatic-specific antigen between 10.1 and 20 ng/ml.
    Morote J; Trilla E; Esquena S; Serrallach F; Abascal JM; Muñoz A; Id M'Hammed Y; de Torres IM
    Eur Urol; 2002 Oct; 42(4):333-7. PubMed ID: 12361897
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Different PSA assays lead to detection of prostate cancers with identical histological features.
    Yurdakul G; Bangma CH; Blijenberg BG; van Zelst BD; Wildhagen MF; van der Kwast TH; Schröder FH
    Eur Urol; 2002 Aug; 42(2):154-8. PubMed ID: 12160586
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Supersensitive PSA-analysis after radical prostatectomy: a powerful tool to reduce the time gap between surgery and evidence of biochemical failure.
    Haese A; Huland E; Graefen M; Huland H
    Anticancer Res; 1999; 19(4A):2641-4. PubMed ID: 10470210
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.